2019

Kardium® announces successful results from the GLOBAL-AF study (Financial Post)

10/08/2019

Global-AF study demonstrated a 76% percent freedom from atrial fibrillation at 12 months after a single treatment with the Globe System.

Read More

Kardium® announces successful results from the GLOBAL-AF study

10/08/2019

October 8, 2019 9:00 AM Pacific Standard Time VANCOUVER, British Columbia — Kardium Inc. today announced that the Globe® Mapping and Ablation System has successfully demonstrated safety and efficacy in the GLOBAL-AF study.  The results of the study were published in the Journal of Cardiovascular Electrophysiology. The study demonstrated a 76% percent freedom from atrial […]

Read More

Kardium Announces New Financing to Commercialize the Globe System for the Treatment of Atrial Fibrillation (Cardiac Vascular News)

02/07/2019

Financing was led by funds and accounts advised by T. Rowe Price Associates, Inc., and included participation from other new and existing Kardium shareholders.

Read More

Kardium® announces new financing to commercialize the Globe® System for the treatment of atrial fibrillation

01/24/2019

T. Rowe Price leads new round of financing together with new and existing investors January 24 2019 10:00 AM Pacific Standard Time VANCOUVER, B.C. – Kardium Inc., developer of the Globe® Mapping and Ablation System for the treatment of atrial fibrillation, announced today that it has raised an undisclosed amount in a new financing round. […]

Read More